Surgical Management of Diffuse Sclerosing Variant of Papillary Thyroid Carcinoma. Experience in 25 Patients
To delineate the clinicopathologic features and biologic behavior of the diffuse sclerosing variant of papillary thyroid carcinoma (DSV-PTC) and to report its outcome.
The clinical records of 25 patients who had surgery for DSV-PTC from 2004 to 2017 were retrospectively analyzed. Comparisons were made to similar studies in the literature reporting ≥8 cases and a cohort of classical PTC.
There were 20 females and 5 males with an average age of 23 years (range 10–39 years). Bilateral disease occurred in 80% of cases. The mean size of the dominant mass was 4.2 ± 1.92 cm. In 92% of cases, therapeutic neck dissection was performed. Male sex significantly correlated with a higher yield of positive lymphadenopathy (p = 0.045). 62% of patients had recurrent disease. Recurrence significantly correlated with male sex, the number of metastatic lymph nodes (cutoff: 22 lymph nodes), and multifocality (p = 0.044, p ˂ 0.008, p ˂ 0.003, respectively). However, it did not correlate with the age at presentation. No disease-specific mortality occurred after an average follow-up of 77 months (range 12–168 months). The two comparisons made demonstrated a statistically significant greater tendency of the current series of DSV-PTC toward more aggressive clinicopathologic features and biologic behavior. No differences in overall survival were observed.
The DSV-PTC should be considered a high-risk PTC that mandates an aggressive therapeutic strategy with the intent of optimizing disease-free survival.
Corresponding author CS studied the concept and design and contributed to data interpretation, drafting, final approval, and accountability for all aspects of the work. LF was involved in data collection and interpretation, drafting, final approval, and accountability for all aspects of the work. SB was involved in data interpretation, drafting, critical revision, final approval, and accountability for all aspects of the work. GE, AB, CC, ML, RM, and SS were involved in data collection and interpretation, final approval, and accountability for all aspects of the work.
This study was not funded by any grant.
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This work was approved by the Ethical Committee at the University of Pisa, Pisa, Italy.
Informed consent was waived due to the retrospective nature of the study.
- 10.Tuttle RM, Haugen B, Perrier ND (2017) Updated American Joint Committee on cancer/tumor-node-metastasis staging system for differentiated and anaplastic thyroid cancer (Eighth edition): what changed and why? Thyroid 27:751–756. https://doi.org/10.1089/thy.2017.0102 CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Spinelli C, Tognetti F, Strambi S, Morganti R, Massimino M, Collini P (2018) Cervical lymph node metastases of papillary thyroid carcinoma, in the central and lateral compartments, in children and adolescents: predictive factors. World J Surg 42:2444–2453. https://doi.org/10.1007/s00268-018-4487-z CrossRefPubMedGoogle Scholar
- 27.Bongiovanni M, Triponez F, McKee TA, Neeta Kumar N, Matthes T, Meyer P (2009) Fine-needle aspiration of the diffuse sclerosing variant of papillary thyroid carcinoma masked by florid lymphocytic thyroiditis; a potential pitfall: a case report and review of the literature. Diagn Cytopathol 37:671–675CrossRefGoogle Scholar